BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PCI Synthesis Completes R&D Expansion of 30%, Adds 20 New Hires & Signs Agreement With Biogen Idec, Inc. (Massachusetts) (BIIB)


12/13/2011 12:02:20 PM

Newburyport, Mass., December 13, 2011 – PCI Synthesis, Inc. (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, announced the successful completion of a major expansion at its Devens, Mass. Research and Development facility.

The expansion, which includes several new research hoods, analytical instruments, additional support equipment, additional staff, and a major expansion to the site's existing kilo lab capacity, was initiated to support PCI’s expanding activities in early- and late-stage clinical candidate programs. Since September 1st, the company has brought on board 20 new staff members in several functional areas to further support its growth in development of new compounds.

All together the additional staff and capacity enables PCI to offer its biotech and pharmaceutical customers a bridge from lab scale development to commercial manufacturing. This represents an important intermediate step as customers work on new compounds for new therapies, conduct clinical trials and seek to bring products to market. The 30-percent capacity increase positions PCI to handle increased customer demand.

Part of the expansion was driven by a new collaboration agreement with Biogen Idec to work closely with its process research group to augment its internal small-molecules capabilities and optimize a number of new compounds.

This expansion follows last month's announcement of an eighth successful FDA inspection of PCI's Newburyport facility and its sixth product pre-approval.

" PCI Synthesis's ongoing investments in our people, our cGMP systems, and our analytical capabilities are paying off. Early stage development has played a significant role in achieving our mission to collaborate with our customers who rely on us to understand the complex dynamics of small-molecule development and manufacturing," said Edward S. Price, President of PCI Synthesis.

About PCI Synthesis

PCI Synthesis is a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in both generic and branded pharmaceuticals. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES